anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a kind of calcium gluconate injection and preparation method thereof, which has steps of：1. putting into calcium gluconate after water for injection is boiled, stirring and dissolving simultaneously keeps one section of fluidized state；2. being slowly added to lactic acid/calcium hydroxide clarified solution under boiling, stirring and dissolving simultaneously keeps one section of fluidized state；3. it is 2.5~3.0 that dilute hydrochloric acid, which adjusts pH value, medicinal carbon is added after boiling, it is 7.5~8.0 that sodium hydroxide solution, which adjusts pH value, adds water for injection, stirs evenly, and is stood, and returns de- charcoal, it is 5.0~6.0 that dilute hydrochloric acid, which adjusts pH value,；4. adding to the full amount of water for injection, stir evenly, refined filtration reflux is cooled to room temperature；5. embedding, sterilizing.For the method for the present invention by the improvement of specially treated and feed way in process for preparation, the especially control of pH can finally solve the problems, such as visible foreign matters existing for calcium gluconate injection, especially in the case of low-temperature storage.
BACKGROUND: Previous studies have shown that patients with pre-existing chronic obstructive pulmonary diseases (COPD) were more likely to be infected with coronavirus disease (COVID-19) and lead to more severe lung lesions. However, few studies have explored the severity and prognosis of COVID-19 patients with different phenotypes of COPD.
PURPOSE: The aim of this study is to investigate the value of the deep learning and radiomics features for the severity evaluation and the nucleic acid turning-negative time prediction in COVID-19 patients with COPD including two phenotypes of chronic bronchitis predominant patients and emphysema predominant patients.
METHODS: A total of 281 patients were retrospectively collected from Hohhot First Hospital between October 2022 and January 2023. They were divided to three groups: COVID-19 group of 95 patients, COVID-19 with emphysema group of 94 patients, COVID-19 with chronic bronchitis group of 92 patients. All patients underwent chest computed tomography (CT) scans and recorded clinical data. The U-net model was pretrained to segment the pulmonary involvement area on CT images and the severity of pneumonia were evaluated by the percentage of pulmonary involvement volume to lung volume. The 107 radiomics features were extracted by pyradiomics package. The Spearman method was employed to analyze the correlation of the data and visualize it through a heatmap. Then we establish a deep learning model (model 1) and a fusion model (model 2) combined deep learning with radiomics features to predict nucleic acid turning-negative time.
RESULTS: COVID-19 patients with emphysema was lowest in the lymphocyte count compared to COVID-19 patients and COVID-19 companied with chronic bronchitis, and they have the most extensive range of pulmonary inflammation. The lymphocyte count was significantly correlated with pulmonary involvement and the time for nucleic acid turning negative (r=-0.145, P < 0.05). Importantly, our results demonstrated that model 2 achieved an accuracy of 80.9% in predicting nucleic acid turning-negative time.
CONCLUSION: The pre-existing emphysema phenotype of COPD severely aggravated the pulmonary involvement of COVID-19 patients. Deep learning and radiomics features may provide more information to accurately predict the nucleic acid turning-negative time, which is expected to play an important role in clinical practice.
With the increased use of radiographic imaging for abdominal complaints the incidental finding of small asymptomatic renal masses has increased. Partial nephrectomy has become the gold standard therapy for treatment of kidney masses ≤7cm in size. Absolute indications for partial nephrectomy include bilateral renal tumors, systemic condition affecting renal function, chronic renal insufficiency and solitary kidney function. Elective indications include masses ≤7cm and normal contralateral kidney function. The procedure can be completed through either laparoscopic or open technique. Complication rates from open and partial nephrectomy have been reported to be about 16% with the most common being urinary leak, postoperative bleeding, renal insufficiency and the need for dialysis.

A major predictor of postoperative complications is the warm ischemia time. This is the length of time the kidney is without blood flow at body temperature. It has been reported that renal and cellular damage of the nephron begins after 20-30 minutes of ischemia. As well, the volume of estimated blood loss has been shown to be a major predictor of postoperative complications. A threshold value of estimated blood loss \>750 mL and warm ischemia time \>45 minutes have been associated with significantly increased rates of postoperative complications. Recent advancements in laparoscopic technique have lead to the development of the early unclamping method of partial nephrectomy. In this method the renal pedicle is unclamped following the initial central running suture but before the defect has been entirely repaired with bolstering sutures. This method has been reported to decrease warm ischemia time by ≥50% in comparison to the traditional technique of unclamping after full closure of the defect.

The investigators have demonstrated the safety of the "Quill" (Angiotech, Vancouver, BC) polydioxanone barbed self retaining sutures in a retrospective series. These sutures contain unidirectionally oriented barbs on the surface that switch direction at the half-way point. Laparoscopic partial nephrectomy is a technically demanding procedure and maintaining tension during intracorporeal suturing is particularly challenging. The barbs of the self retaining sutures lock into the tissue allowing the surgeon to preserve tissue approximation without needing to maintain tension. The investigators believe these sutures will allow the surgeon to obtain greater tissue approximation therefore decreasing postoperative urinary leakage and bleeding. These findings need to be validated postoperatively.

The investigators believe that coupling the shorter warm ischemia time of the early unclamping method and the greater tissue approximation afforded by the self retaining sutures will result in fewer complications following partial nephrectomy.
The greatest challenge in implantology is to achieve a satisfactory esthetic result. A new platelet concentrate protocol, named Leucocyte and platelet-rich Fibrin (L-PRF), has been developed in France. Research has shown positive results using L-PRF during implant placement, as improving soft tissue healing and bone formation, leading to higher esthetic level and greater implant stability. The aim of this study is to evaluate if the use of PRF associated to implant placement in esthetic area presents superior aesthetic result and soft tissue thickness increase when compared to implant placement without graft. Forty-two patients requiring single implant placement in the esthetic area of the maxilla will be randomly divided into test group (implant + L-PRF) and control group (implant without graft). Surgical procedures will be performed by a single operator. The rates of soft tissue thickness, esthetic and comfort will be evaluated at baseline and 3 months after the procedure.
FIELD: medicine, pharmacy. SUBSTANCE: agent comprises zopiclone as an active component and the following special accessory components: microcrystalline cellulose, lactose, modified starch or croscarmellose, starch, aerosil and stearic acid or its salts. Agent is made as a tablet with film enveloper as a coating. The novel agent with defined ratio of components provides optimal physical-chemical and technological properties of medicinal formulation and high bioavailability of medicinal substance. Agent is used in treatment of insomnia, hardened fall sleeping, night waking up, early waking up, sleep disturbances in psychic disorders. EFFECT: valuable medicinal properties of agent. 5 cl
Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
Recent research from our laboratory has detected novel findings concerning damage to mitochondria within skeletal muscle in type 2 diabetes (type 2 DM), damage that is evident morphologically and by functional criteria. In this project, we propose, firstly, to more fully test this hypothesis of an impaired bio-energetic capacity, and to begin to examine the pathogenesis of damage to mitochondria in type 2 DM. We are also interested in assessing the potential for reversing damage, and improving functional capacity of mitochondria through a weight loss or a combined exercise and weight loss intervention.

The first specific aim is to measure the functional capacity of mitochondria in human skeletal muscle in type 2 DM and in those at apparent risk for type 2 DM (obese, sedentary, non-diabetic adults with the Metabolic Syndrome and/or impaired glucose tolerance). The second specific aim is to examine the morphology of mitochondria in human skeletal muscle in type 2 DM and in those at apparent risk for type 2 DM. The third specific aim is to examine the pathogenesis of mitochondrial damage in type 2 DM and in those at apparent risk for type 2 DM. The fourth specific aim is to assess whether exercise and diet can improve mitochondrial function and morphology in type 2 DM and in those at apparent risk for type 2 DM.
Health care workers play an essential role in maintaining the public trust in vaccination programmes globally, and more specifically, in low- and middle-income countries. This role is particularly important in building trust in the human papillomavirus (HPV) vaccine. While there are many factors that affect HPV vaccine acceptance, health care workers are one of the most critical influences in the decision-making process among parents as well as adolescent girls. In this paper, we sought to better understand how health care workers in a diverse set of countries communicate and promote HPV vaccines. We summarize communication approaches and lessons learned by health care workers in Kenya, India, and Nigeria through a case study approach. In Kenya, the utilization of a multisectoral approach proved to be very important. In India, intense social mobilization with targeted messaging by target audience laid the groundwork for community acceptance. An evolving communication strategy was essential in Nigeria, where there is no national HPV vaccination programme. Given the increase in vaccine hesitancy globally, the lessons learned through these three country examples highlight the importance of communication efforts in increasing vaccine acceptance.
All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, oncology, also can be used for treating premalignant diseases of female genital organs. For this purpose, each session involves an injection of a dosage of mixed organ preparations. Then, an affected organ is exposed to laser radiation. A dose is partially delivered paracervically. Another portion of the dose is introduced by injections into a pathology region. In 10-15 minutes, the pathology region is coated with a photosensitiser or/and the latter can be introduced orally or/and intravenously. In 1-3 hours, this organ is exposed to laser for 7-15 minutes. Additionally for 10-25 minutes, a small pelvis and sacral bone region is exposed to cytoluminescent therapy (CLT) lamps. 1-3 sessions a week of the introduction of the mixed organ preparations are combined with activation by laser radiation and by CLT lamps. The therapeutic course is 10-15 sessions. ^ EFFECT: method provides effective treatment of premalignant diseases of the female genital organs and ensures a prolonged effect not requiring hormonotherapy. ^ 6 cl, 6 ex
Diethylamine salicylate monohydrate is prepared by mixing together salicylic acid, diethylamine, water and acetone, and cooling to-15 DEG C. Hydrates of diethylamine 2-hydroxy-m-toluate and diethylamine 2, 5-dihydroxybenzoate are prepared by evaporating an aqueous solution of the amine salt to a thick syrup, cooling to crystallizing point, filtering off the crystals obtained, and then draining and air-drying the crystals.  Specification 790,762 is referred to.ALSO:Pharmaceutical compositions suitable for the treatment of rheumatic disorders comprise a solid or liquid solution of salicylamide in a solvent consisting of or containing an amine salt of an hydroxy aromatic acid of the formula <FORM:0976393/A5-A6/1> where any one of the five substituents R1, R2, R3, R4 and R5 is an -OH group, the remaining four being hydrogen, -OH groups or alkyl groups with not more than three carbon atoms, R6 is an alkyl group with not more than two carbon atoms, and R7 and R8 are hydrogen or alkyl groups with not more than two carbon atoms.  The compositions may include water and water-miscible solvents such as alcohols, glycols and polyoxyethylene glycols.  The compositions may be in the form of simple solid or liquid solutions, and also emulsions, ointments, pastes, sprays or jellies.  Amine salts specified are diethylamine salicylate, diethylamine 2,5-dihydroxybenzoate and diethylamine 2-hydroxy-m-toluate. Optional ingredients mentioned in some of the examples are ethyl nicotinate (a rubefacient) together with neroli perfume.  According to the Provisional Specification, the amide active ingredient can be any substituted benzamide having at least one hydroxy group and, optionally, one or more lower alkyl groups in the benzene ring.  Specification 790,762 is referred to.
Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
Stabilized enzyme preparations comprise a minor amount of poly-L-lysine and/or albumin and/or protamine.  The poly-L-lysine and protamine may be used in the form of salts with organic or inorganic acids.  Lysozyme and glucuronoglycosaminoglycan-hyaluronate-lyase may be so stabilized.ALSO:Enzymes, e.g. glucuronoglycosaminoglycanhyaluronate-lyase or lysozyme, are stabilised by addition of albumin, or of poly-L-lysine or protamine or salts thereof with organic or inorganic acids.  Such stabilised enzyme solutions may be used therapeutically by intravenous or intramuscular injection or by scanification.  Compositions may also contain glucose, invert sugar, or wetting, emulsifying and dispersing agents.
Examples of apparatus, methods, and compositions for endodontic treatments are described. The apparatus can include a fluid platform configured to substantially retain fluid in a tooth chamber during treatment. The fluid platform can help maintain fluid circulation in the tooth chamber as fluid flows into and out of the tooth chamber. The apparatus can also include a pressure wave generator configured to generate acoustic waves that can be used for cleaning root canals and tooth surfaces in the tooth chamber. An access opening can be formed, and the pressure wave generator can be used to remove organic material from the tooth chamber. In some treatments, after cleaning, the tooth chamber can be only partially filled by an obturation material. In other treatments, substantially the entire tooth chamber can remain unfilled by the obturation material. After cleaning the tooth, the access opening can be sealed, using, e.g., a coronal seal.
This arm consists of 6 individual educational sessions taking place every 2 weeks for a total of 12 weeks which will be scheduled to accommodate clinicians schedule and preferences. These sessions will be led by a member of the clinical informatics team and target optimization of the EHR. The sessions will be conducted on site, virtually, or a combination of both onsite and virtual. Between sessions participants are to note any challenges, questions, or recommendations related to the EHR. If participant misses 2 sessions, they will be asked to reschedule, but if they miss 3 sessions they may be asked to withdraw from the intervention.
Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
Ph-negative Myeloproliferative Neoplasm is a rare yet dangerous disease that can turn into more severe forms of disorders later on. Clinical diagnosis of the disease exists but often requires collecting multiple types of pathologies which can be tedious and time-consuming. Meanwhile, studies on deep learning-based research are rare and often need to rely on a small amount of pathological data due to the rarity of the disease. In addition, the existing research works do not address the data scarcity issue apart from using common techniques like data augmentation, which leaves room for performance improvement. To tackle the issue, the proposed research aims to utilize distilled knowledge learned from a larger dataset to boost the performance of a lightweight model trained on a small MPN dataset. Firstly, a 50-layer ResNet model is trained on a large lymph node image dataset of 3,27,680 images, followed by the trained knowledge being distilled to a small 4-layer CNN model. Afterward, the CNN model is initialized with the pre-trained weights to further train on a small MPN dataset of 300 images. Empirical analysis showcases that the CNN with distilled knowledge achieves 97% accuracy compared to 89.67% accuracy achieved by a clone CNN trained from scratch. The distilled knowledge transfer approach also proves to be more effective than more simple data scarcity handling approaches such as augmentation and manual feature extraction. Overall, the research affirms the effectiveness of transferring distilled knowledge to address the data scarcity issue and achieves better convergence when training on a Ph-Negative MPN image dataset with a lightweight model.
Store at 25°C (77°F). Excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Protect from freezing. Avoid excessive heat. 

Each bag contains no preservative. Once drug has been withdrawn from ready-to-use bag, the bag should be used within 24 hours, with any unused portion discarded. 

Do not use plastic containers in series connections. Such use could result in an embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. 

Do not remove unit from overwrap until ready to use. Do not use if overwrap has been previously opened or damaged. The overwrap is a moisture barrier. The inner bag maintains sterility of the solution. Tear overwrap at notch and remove premixed bag. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. 

Check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. Do not use unless the solution is clear (colorless to light yellow) and the seal is intact. 

Preparation for intravenous administration:

Use aseptic technique. 

Suspend premixed bag from eyelet support. 

Remove plastic protector from delivery port at bottom of bag. 

Attach administration set. 

Refer to complete directions accompanying set.
Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
Improvement in the assessment techniques, to enable better pain management in children with intellectual and developmental disabilities who are unable to describe the intensity of the postsurgical pain, is a cornerstone of our research program. This research project will elucidate the regulation of specific markers of global surgical insult (nociception, inflammation, stress responses) associated to specific physiological mechanisms related to pain in children with and without verbal skills undergoing major orthopaedic surgery. This project creates a unique opportunity to directly characterize and compare MSK and surgical pain subjectively in the two different patient samples (verbal and non-verbal). As molecular events of pathophysiological processes are quantifiable, the investigators will test for associations between the expression of front-running pain biomarkers in physiological fluids (blood and saliva) and the experience of pain in two patient samples (verbal and non-verbal) undergoing major orthopaedic surgery. The identification of biomarkers will provide a deeper understanding of a patient's pain perception alongside self-report or observers' report subjective measurements. Even with standardization of best practice perioperative anesthetic pain management, children undergoing similar surgical procedures experience pain at different intensity. Based on preliminary findings, treatment modalities appear to be ineffective in one out of five patients. Pain experience variability may originate in the lack of rigor in the clinical pain assessment tools. Tools such as numerical rating scales used in the perioperative period are not based on objective patient specific pain thresholds. A personalized mechanism-based approach may be the key to better identify a patient's postsurgical pain outcome and how this assessment could lead to personalized perioperative pain management. The ultimate goal is to use this information to offer the highest quality of pain control in children with MSK conditions, and more specifically in children with limited communication skills unable to communicate their distress associated with the surgical procedures.